BMI View: Although Mexico has made great efforts to improve its regulatory framework and create a more
hospitable business environment to entice pharmaceutical companies, it is still hard for multinationals to
fully materialise their commercial benefit due to the sign ..."
BMI View: We identified Mexico as 'the most promising emerging pharmaceutical market' in September
2013, Shortly after this, the approval of the energy reform bill reinforced our view that, over the long term,
healthier fiscal revenue will encourage the government to ..."
BMI View: Mexico's encouraging macroeconomic growth prospects, business-friendly environment and
improving pharmaceutical regulatory regime have made it an increasingly attractive market to
multinationals. Apart from the ageing population and the increasing incidence ..."
BMI View: Under the Pacific Alliance agreement, Chile, Peru and Colombia will recognise medicine
registrations issued by COFEPRlS and allow easy entry to pharmaceutical products approved by the
organisation. Mexico's well-recognised drug approval standard among Latin American c ..."
BMI View: The improving performance of Mexico's regulatory system presents more opportunities for multinational pharmaceutical companies seeking to enter the Mexican pharmaceutical market. On the back of favourable economic and political conditions, we forecast Mexico's pharmaceu ..."
BMI View: Mexico's relatively low-cost business environment, growing domestic pharmaceutical market
and the improving regulatory regime have made it an attractive market to multinationals. The improved
performance by market regulator COFEPRIS has allowed Mexico to acquire a rep ..."
The improving regulatory environment and the increasing foreign direct investment make Mexico's pharmaceutical market more attractive to multinational drugmakers. We project an increase in government healthcare spending to further boost the number of procedures and expand access ..."